Quick Answer
InMed Pharmaceuticals Inc. reported Total Revenue of $4.94 million for fiscal year 2025.
InMed Pharmaceuticals Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $4.94M +7.5% |
$4.60M +11.2% |
$4.14M +279.6% |
$1.09M | — | — |
| Net Income | -$8.16M -6.3% |
-$7.68M +3.4% |
-$7.95M +57.3% |
-$18.60M -82.3% |
-$10.20M -14.1% |
-$8.94M |
| Diluted EPS | -$8.36 +58.5% |
-$20.14 -519.7% |
-$3.25 +90.2% |
-$33.17 +12.6% |
-$37.96 | — |
| Total Assets | $15.58M +31.8% |
$11.82M -16.2% |
$14.11M +10.3% |
$12.79M +30.7% |
$9.78M +25.4% |
$7.80M |
| Cash and Equivalents | $11.08M +68.5% |
$6.57M -26.3% |
$8.91M +44.3% |
$6.18M -16.1% |
$7.36M +26.8% |
$5.81M -41.0% |
| Stockholders Equity | $13.43M +45.9% |
$9.21M -23.9% |
$12.09M +33.2% |
$9.08M +23.1% |
$7.38M +25.5% |
$5.88M -58.7% |
| R&D Expense | $2.85M -11.3% |
$3.22M -13.8% |
$3.73M -48.8% |
$7.28M +36.4% |
$5.34M -8.1% |
$5.81M |
| Gross Profit | $1.71M +55.0% |
$1.10M -21.5% |
$1.40M +158.1% |
$543.5K | — | — |
| Shares Outstanding | 2.00M +349.0% |
445,908 -86.6% |
3.33M +411.5% |
650,667 +102.1% |
322,028 -93.8% |
5.22M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | December 31, 2025 | $820.2K | -26.2% | -26.8% |
| Net Income | December 31, 2025 | -$2.03M | +21.2% | -17.4% |
| Diluted EPS | December 31, 2025 | -$0.51 | +86.0% | -15.9% |
| Total Assets | December 31, 2025 | $11.19M | +31.6% | -16.2% |
| Cash and Equivalents | December 31, 2025 | $6.95M | +103.4% | -25.5% |
| Stockholders Equity | December 31, 2025 | $9.59M | +55.1% | -17.3% |
| R&D Expense | December 31, 2025 | $630.6K | -29.6% | +8.4% |
| Gross Profit | December 31, 2025 | $184.2K | -60.0% | -54.3% |
| Shares Outstanding | December 31, 2025 | 2.80M | +287.2% | +7.7% |
- InMed Pharmaceuticals Inc. reported Total Revenue of $4.94 million for fiscal year 2025.
- InMed Pharmaceuticals Inc. showed an increase of +7.5% in Total Revenue compared to the prior fiscal year.
- InMed Pharmaceuticals Inc. reported Net Income of -$8.16 million for fiscal year 2025.
- InMed Pharmaceuticals Inc. showed a decrease of -6.3% in Net Income compared to the prior fiscal year.
- InMed Pharmaceuticals Inc. reported Diluted EPS of $8.36 per share (loss) for fiscal year 2025.
- InMed Pharmaceuticals Inc. showed an increase of +58.5% in Diluted EPS compared to the prior fiscal year.
- InMed Pharmaceuticals Inc. reported Total Assets of $15.58 million for fiscal year 2025.
- InMed Pharmaceuticals Inc. showed an increase of +31.8% in Total Assets compared to the prior fiscal year.
- InMed Pharmaceuticals Inc. reported Cash and Equivalents of $11.08 million for fiscal year 2025.
- InMed Pharmaceuticals Inc. showed an increase of +68.5% in Cash and Equivalents compared to the prior fiscal year.
- InMed Pharmaceuticals Inc. reported Stockholders Equity of $13.43 million for fiscal year 2025.
- InMed Pharmaceuticals Inc. showed an increase of +45.9% in Stockholders Equity compared to the prior fiscal year.
- InMed Pharmaceuticals Inc. reported R&D Expense of $2.85 million for fiscal year 2025.
- InMed Pharmaceuticals Inc. showed a decrease of -11.3% in R&D Expense compared to the prior fiscal year.
- InMed Pharmaceuticals Inc. reported Gross Profit of $1.71 million for fiscal year 2025.
- InMed Pharmaceuticals Inc. showed an increase of +55.0% in Gross Profit compared to the prior fiscal year.
- InMed Pharmaceuticals Inc. reported Shares Outstanding of 2.00 million shares for fiscal year 2025.
- InMed Pharmaceuticals Inc. showed an increase of +349.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: